The massive overhang of up to 350 million registered shares (pre-split) creates significant near-term selling pressure risk once the registration becomes effective and the lock-up period ends. Monitor for any selling by major holders like Third Rock Ventures, Alpha Wave, and RA Capital, which hold the largest blocks. The 180-day lock-up for certain insiders provides some near-term protection, but many PIPE investors are not locked up and may sell immediately after conversion on December 2, 2026.
Drugs in focus
LSTA drug pipeline →MAR001/005
● Neutral Named in this S-3/A- Impact
- Phase
- Phase 2b
- Time to market
- At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
- Next catalyst
- None dated
What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.
Price Chart
How similar events traded
Executive Summary
Lisata Therapeutics filed Amendment No. 1 to its S-3 registration statement to register up to 350,498,987 shares of common stock for resale by selling stockholders. These shares were issued in connection with the September 2026 acquisition of Marea Therapeutics and a concurrent $225 million PIPE financing. The company will not receive any proceeds from the resale, but the registration enables selling stockholders (primarily former Marea equity holders and PIPE investors) to sell their shares after conversion of Series C preferred stock, expected on December 2, 2026, following stockholder approval and a 1-for-15 reverse stock split effective November 23, 2026.
Key Facts
- Registers up to 350,498,987 shares of common stock for resale by selling stockholders.
- Shares consist of 1,679,366 Merger Common Shares, 197,951,626 Merger Conversion Shares, and 150,867,995 Private Placement Conversion Shares.
- Series C preferred stock (each share convertible into 1,000 common shares) was issued in the Marea acquisition and a $225 million PIPE financing.
- Conversion of Series C preferred stock and resale registration are subject to stockholder approval of conversion and a 1-for-15 reverse stock split (approved Nov 9, 2026, effective Nov 23, 2026).
- Company will not receive any proceeds from the resale; selling stockholders include major healthcare-focused funds.
- As of November 1, 2026, the company had 10,804,066 shares of common stock outstanding (pre-reverse split).
- The potential resale shares represent approximately 32.4 times the current outstanding share count on a pre-reverse split basis, implying massive potential dilution.
- A 180-day lock-up agreement applies to certain officers, directors, and stockholders, but does not cover all selling stockholders.
- The company expects to change its name to Marea Therapeutics, Inc. and its ticker to MREA on December 2, 2026.
Financial Impact
Up to 350,498,987 shares registered for resale, representing approximately 3,244% of the 10.8 million shares outstanding as of November 1, 2026 (pre-reverse split). The PIPE raised $225 million at $1.49137 per common share equivalent.
Risk Factors
- Extreme dilution risk: registered shares represent over 30 times current outstanding shares (pre-split), which could severely depress the stock price if a significant portion is sold.
- Near-term selling pressure from PIPE investors and former Marea stockholders who are not subject to lock-up agreements.
- The reverse stock split (1-for-15) may reduce share count but does not change the fundamental overhang; post-split, the registered shares would represent approximately 23.4 million shares vs. 720,271 outstanding.
- The company's small $11 million market cap makes it vulnerable to large sell orders.
- No proceeds to the company from the resale, so the registration provides no capital to fund operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001140361-26-044932 |
| Document: ny20085403x2_ex5-1.htm | 0001140361-26-044932 |
| Document: ny20085403x2_ex23-2.htm | 0001140361-26-044932 |
| Document: ny20085403x2_ex23-1.htm | 0001140361-26-044932 |
| Document: 0001140361-26-044932-index-headers.html | 0001140361-26-044932 |
| Document: 0001140361-26-044932-index.html | 0001140361-26-044932 |
| Document: 0001140361-26-044932.txt | 0001140361-26-044932 |
Track record
21 reports on LSTA
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 19, 20262d ago S-3/A Bearish 6/10 Viewing Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
- Nov 19, 20262d ago 8-K Bearish 5/10 Entry $0.9100 settles Feb 18
- Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
- Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
- Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
- Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
- Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
- Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers